Daylife Select
A point & click tool to create dynamic content portals. Learn More »
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
Trials Showed Merck & Co. , Inc. Full Article at Biospace
David Gardner called it. He’s up 1,334%! See what David’s recommending that you buy NEXT. Merck (NYSE: MRK) increased its share count by almost 45% to pay for the acquisition of Schering-Plough. Now it's planning to buy some of that stock back. Full Article at Motley Fool
FILE - In this June 17, 2005 file photo, Merck & Co. CEO Richard T. Clark, answers a question at the drug maker's Whitehouse Station, N.J. headquarters. View Photo »
The positive opinion by the CHMP for marketing approval in Europe of Merck's CTP version of the fertility drug FSH is a major milestone that serves to validate the utility of our CTP technology platform for the development of superior long-acting protein therapeutics ... We are optimistic that ELONVA's ...
NEW YORK — Idera Pharmaceuticals Inc. on Wednesday announced the end of a research partnership with Novartis AG, but said Merck & Co. is extending its work with Idera for another year. Full Article at Newsvine
Drugmaker Merck & Co. (NYSE: MRK) declared a quarterly dividend of 38 cents on Tuesday, and said it plans to buy back as much as $3 billion in stock, according to Associated Press. Full Article at TransWorldNews
The Food and Drug Administration is keeping a close watch on drug companies so that they don't cross federal marketing restrictions. These restrictions currently don't allow drug companies to participate in online social sites. Full Article at Associated Content
Traders look to buy and sell shares of Merck stock at the New York Stock Exchange Wednesday, March 18, 2009, in New York. View Photo »
The creation of the China R&D center marks a new milestone in Merck Serono's commitment to China, where there is a rising demand for more health care options
But one big question remained: How would doctors and patients react in the real world? Now we have that answer: They pulled back from the Merck meds. Full Article at FiercePharma
During oral arguments to the US Supreme Court on November 30th, Merck & Co will seek dismissal of a Vioxx securities fraud class action by arguing that plaintiffs should have known more than two years before filing suit in November 2003 that the... Full Article at Scrip News
There are no results for this module. Edit this module to change the search term used to query Wikipedia
FILE - In this June 17, 2005 file photo, Merck & Co. CEO Richard T. Clark, answers a question at the drug maker's Whitehouse Station, N.J. headquarters.
View Photo »Traders look to buy and sell shares of Merck stock at the New York Stock Exchange Wednesday, March 18, 2009, in New York.
View Photo »In this May 22, 2008 file photo, Merck & Co. headquarters is seen in Whitehouse Station, N.J. Merck & Co. is buying Schering-Plough Corp. for $41.1 billion in stock and cash, Monday, March 9, 2009, in a deal that gives the companies more firepower to compete in a drug industry facing s...
View Photo »This handout image shows the logo for Merck & Co. ,Inc. US pharmaceutical giants Merck and Schering-Plough announced their merger on March 9, 2009 in a stock-and-cash transaction valued at 41.1 billion dollars.
View Photo »Graphic shows product sales figures for Merck & co. and Schering-Plough Corp. 1c x 5 1/4 inches; 46.5 mm x 133 mm;.
View Photo »A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. �EUTERS/Jeff Zelevansky.
View Photo »A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines.
View Photo »A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines.
View Photo »A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines.
View Photo »Richard Clark, Chairman and C.E.O. of Merck, is shown in this undated handout image released by Merck on March 9, 2009.
View Photo »This undated handout image, provided by Merck & Co. Inc. on March 9, 2009, shows the cholesterol drug Vytorin.
View Photo »This undated handout image, provided by Merck & Co. Inc. on March 9, 2009, shows the cholesterol drug Zetia.
View Photo »Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this file photo taken November 19, 2008.
View Photo »Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this file image taken November 19, 2008.
View Photo »Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co. , Inc. , speaks at the Reuters Health Summit in New York, November 10, 2009.
View Photo »Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co. , Inc. , speaks at the Reuters Health Summit in New York, November 10, 2009.
View Photo »File - In this combo made from file photos, the company logos for drugmakers Merck & Co. and Schering-Plough Corp. are seen outside the companies' New Jersey headquarters.
View Photo »File - In this combo made from file photos, the company logos for drugmakers Merck & Co. and Schering-Plough Corp. are seen outside the companies' New Jersey headquarters.
View Photo »File - In this combo made from file photos, the company logos for drugmakers Merck & Co. and Schering-Plough Corp. are seen outside the companies' New Jersey headquarters.
View Photo »In this combo made from file photos, the company logos for drugmakers Merck & Co. and Schering-Plough Corp. are seen outside the companies' New Jersey headquarters.
View Photo »FILE - In this 2004 file photo provided by Schering-Plough Corp. , the cholesterol-lowering drug Vytorin, the product of a joint venture between pharmaceutical companies Merck & Co. , and Schering-Plough Corp. , is shown.
View Photo »FILE -- In this May 11, 2009 file photo, President Barack Obama, center, speaks about health care in the State Dining Room of the White House in Washington.
View Photo »FILE -- In this May 11, 2009 file photo, President Barack Obama, center, speaks about health care in the State Dining Room of the White House in Washington.
View Photo »FILE -- In this May 11, 2009 file photo, President Barack Obama, center, speaks about health care in the State Dining Room of the White House in Washington.
View Photo »FILE - In this April 28, 2006 file photo, a bottle of Schering-Plough's allergy spray Nasonex is shown in New York.
View Photo »Traders look to buy and sell shares of Merck stock at the New York Stock Exchange Wednesday, March 18, 2009, in New York.
View Photo »The positive opinion by the CHMP for marketing approval in Europe of Merck's CTP version of the fertility drug FSH is a major milestone that serves to validate the utility of our CTP technology platform for the development of superior long-acting protein therapeutics ... We are optimistic that ELONVA's ...
The creation of the China R&D center marks a new milestone in Merck Serono's commitment to China, where there is a rising demand for more health care options
Innovation in OLED technology is one of the primary focuses of our institute ... We’re pleased to partner with Applied Materials and Merck to evaluate how our new high-efficiency OLED lighting device structures will perform in an industrial-scale environment.
We would encourage parents to report any adverse experience associated with any Merck medication or vaccine to their healthcare provider, Merck or the FDA. Patients can report adverse events through their healthcare provider, the Merck National Service Center (1-800-444-2080), or FDA MEDWatch or call 1-...
We would encourage parents to report any adverse experience associated with any Merck medication or vaccine to their healthcare provider, Merck or the FDA. Patients can report adverse events through their healthcare provider, the Merck National Service Center (1-800-444-2080), or FDA MEDWatch or call 1-...
The combination of the considerable talents of Schering-Plough and Merck employees across the globe positions Merck to move through this dynamic time for our industry with a clear vision for the future.
We are excited about the results that have been obtained thus far in the collaboration with Merck. Considering the complexity of the target, we believe that the results demonstrate the value of having access to hundreds of millions to billions of small molecules for screening ... It is a great pleasure ...
We are excited about the results that have been obtained thus far in the collaboration with Merck. Considering the complexity of the target, we believe that the results demonstrate the value of having access to hundreds of millions to billions of small molecules for screening ... It is a great pleasure ...
Merck certainly has the right to participate in the government process, but it is important to have watchdog groups involved as well, to ensure that monied interests do not overwhelm the process and that women's health remains the overriding priority.
I launched in partnership with Merck at USCA last year, and I am proud to be in San Francisco to come full circle with this impactful campaign ... Through , I hope to highlight the importance for people living with HIV to have a positive outlook on life while effectively managing their disease and to co...
Dr. Paul Offit of the Children's Hospital of Philadelphia (CHOP) took home a fortune of at least $29 million as part of a $182 million sale by CHOP of its worldwide royalty interest in the Merck Rotateq vaccine to Royalty Pharma in April of last year.
The consent order announced today addresses the competitive concerns related to Schering-Plough's proposed acquisition of Merck
Cuban children suffering from lymphoblastic leukemia who reject traditional medicines can not be treated with the American product 'Elspar', created specially to treat intolerance ... Consequently, the life expectancy of these children is reduced and their suffering increases. The U.S. government forbid...
TC-5214 is a unique form of an old Merck drug called 'mecamylamine,' once used to treat severe hypertension in the 1950s ... Because later research suggested that mecamylamine interacted with brain nicotine receptors, we thought it might have a variety of therapeutic effects similar to nicotine, but wit...
We are pleased to celebrate success in reaching another milestone with our valued partner, Merck
Even in our chemical businesses, which were substantially impacted by the economic crisis, we see a clear trend toward recovery. We now can say with confidence that Merck will deliver what it promised earlier in the year
Given the challenges that Merck was having with its own late-stage pipeline and expected growth drivers such as Gardasil and Singulair, the acquisition could not have come at a more opportune time for the company
This quarter we delivered operational top-line growth, reconciled bottom-line growth and major pipeline successes. We powered through - even in the face of tough global economic and currency headwinds ... As we near the anticipated close of our combination with Merck, we are proud of how our colleagues ...
Merck Forest rarely has problems and there are lots of very content people enjoying the cabins
Merck's ongoing commitment to the HIV community is demonstrated through , which highlights the importance for people living with HIV to have a positive outlook on life while effectively managing their disease ... Philadelphia has been greatly impacted by HIV and I am proud to be partnering with Merck to...
For example, rimonabant, a Sanofi-Aventis drug once viewed a surefire blockbuster, failed to win F.D.A. approval in 2007 because of links to depression and suicidalthoughts. The drug, also known as Acomplia, was then taken off the market in Europe. And Merck and Pfizer abandoned their efforts to develop...
We’re honored to share this award recognizing the creative and collaborative efforts of the Merck/Phase Forward team
There are no results for this module. Edit the module to change the search term used to query Twitter.
